Mois : avril 2019

Les Nouveaux Produits de Synthèse : Essayer la régulation des usages…, Pierre Chappard et Martine Lacoste,

Supplément Technique : Les Nouveaux Produits de Synthèse Essayer la régulation des usages…. L’arrivée des produits que l’on appelle les « Research Chemicals » ou « legal high » n’est pas un hasard. Elle correspond à une évolution de la société addictogène qui se décline sur plusieurs éléments : - Une nouvelle génération s’est emparée de l’outil Internet et passe énormément de temps « online », dans le monde de la « toile » où continue de s’exprimer une quête de plaisir. Cette nouvelle génération d'usagers partage ses expériences d'usage de NPS à travers des forums internet d'auto-support et acquiert une réelle expertise. - [...]

Lire la suite

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes, Ethan B. Russo, 2016

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes Ethan B. Russo Cannabis and Cannabinoid Research, 2016, 1, 1, 2016 DOI: 10.1089/can.2016.0009 Abstract : Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. The commonality in symptomatology in these conditions displaying hyperalgesia [...]

Lire la suite

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, Daniele Piomelli , 2015

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo Daniele Piomelli and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, 1, 1, 44-46 https://doi.org/10.1089/can.2015.29003.ebr   Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held faculty appointments in [...]

Lire la suite

Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain, Natasha R. Ryz et al., 2017

Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain Natasha R. Ryz, David J. Remillard, Ethan B. Russo Cannabis and Cannabinoid Research, 2017, 2, 1, ReviewOpen Access https://doi.org/10.1089/can.2017.0028 Abstract Introduction: The roots of the cannabis plant have a long history of medical use stretching back millennia. However, the therapeutic potential of cannabis roots has been largely ignored in modern times. Discussion: In the first century, Pliny the Elder described in Natural Histories that a decoction of the root in water could be used to relieve stiffness in the joints, gout, and related conditions. By the 17th century, various herbalists were recommending cannabis root [...]

Lire la suite

The Use of Cannabis for Headache Disorders, Bryson C. Lochte et al., 2017

The Use of Cannabis for Headache Disorders Bryson C. Lochte, Alexandre Beletsky, Nebiyou K. Samuel, Igor Grant Cannabis and Cannabinoid Research, 2017, Vol. 2, No 1., 61-71   https://doi.org/10.1089/can.2016.0033 Abstract Headache disorders are common, debilitating, and, in many cases, inadequately managed by existing treatments. Although clinical trials of cannabis for neuropathic pain have shown promising results, there has been limited research on its use, specifically for headache disorders. This review considers historical prescription practices, summarizes the existing reports on the use of cannabis for headache, and examines the preclinical literature exploring the role of exogenous and endogenous cannabinoids to alter headache pathophysiology. Currently, there is not [...]

Lire la suite

New Therapy for Treatment-Resistant Depression, Feyza Sancar, JAMA, 2019,

New Therapy for Treatment-Resistant Depression Feyza Sancar JAMA, 2019, 321, 15, 1449. doi:10.1001/jama.2019.3596 https://jamanetwork.com/journals/jama/fullarticle/2730598   The FDA has approved esketamine nasal spray as an adjunctive therapy for adults with treatment-resistant depression (TRD), which affects approximately 30% of patients with major depressivedisorder. It’s the first regulatory approval of esketamine, the s-enantiomer of ketamine, for any psychiatric condition worldwide. “There has been a long-standing need for additional effective treatments for treatment resistant depression, a serious and lifethreateningcondition,” Tiffany Farchione,MD, acting director of the FDA’s Division of Psychiatry Products, said in a statement. Marketed as Spravato, the drug is indicated for patients whose depressive symptoms haven’t improved [...]

Lire la suite

Dossier : le Cannabis et la vision, Le Cannabiste.com, 2018

Dossier : le Cannabis et la vision Le Cannabiste.com https://lecannabiste.com/dossier-le-cannabis-et-la-vision/ 4 juillet 2018 jean-pierre Si vous posez la question à des utilisateurs réguliers de Cannabis, la plupart vous répondra que l’usage de cette plante constitue pour eux une source de confort et de bien-être. Pour autant nous savons tous que l’usage du Cannabis n’est pas sans incidence sur le corps humain. Les implications du Cannabis sur l’organisme sont nombreuses et parfois plus complexes qu’il n’y paraît. Dans cet article nous nous allons nous intéresser de plus près à l’état des connaissances et aux événements marquants qui ont émaillé la recherche dans le domaine si particulier, [...]

Lire la suite

Etude “Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures, Mark A. Twardowski et al.”: la consommation de cannabis peut poser problème en cas d’anesthésie, Newsweed.fr, 2019

Etude : la consommation de cannabis peut poser problème en cas d’anesthésie Newsweed.fr, Etudes 16 avril 2019 Camille Lezaun https://www.newsweed.fr/etude-cannabis-anesthesie/ Une étude récente (https://www.grecc.org/publications/essais-cliniques/effects-of-cannabis-use-on-sedation-requirements-for-endoscopic-procedures-mark-a-twardowski-et-al-2019/) publiée dans le journal de l’Association Américaine d’Ostéopathie a trouvé que la consommation de cannabis pouvait modifier la tolérance de certains patients aux sédatifs. En effet, selon cette étude, les consommateurs de cannabis ont besoin de doses en moyenne deux fois plus importantes que les non-consommateurs. Cette découverte pourrait avoir des répercussions importantes sur la pratique médicale. L’étude L’étude s’est tenue au Colorado qui a légalisé le cannabis récréatif en 2012. Les chercheurs ont étudié les fichiers de plusieurs patients ayant [...]

Lire la suite

Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures, Mark A. Twardowski et al., 2019

Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures Mark A. Twardowski, Margaret M. Link,  Nicole M. Twardowski The Journal of the American Osteopathic Association, 2019 (Published online April 15, 2019). doi:10.7556/jaoa.2019.052   Context : Cannabis (or marijuana) became legal for recreational use in Colorado in 2012, and this legislation change has created both challenges and opportunities in medicine. More patients are using cannabis, and more patients are now willing to admit cannabis use than in the past, which increases the likelihood that they will be forthcoming about use during medical questioning. Cannabis use may have implications during medical care, including procedural sedation. Objective : [...]

Lire la suite

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition, María M Caffarel et al., 2010

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, Gema Moreno-Bueno, Juana M Flores, Isabel García-Real, José Palacios, Santos Mañes, Manuel Guzmán, Cristina Sánchez Molecular Cancer, 2010, 9, 196 http://www.molecular-cancer.com/content/9/1/196   Abstract Background : ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this [...]

Lire la suite